Seegene Inc, a South Korea-based developer of molecular diagnostics (MDx) solutions, announced on Tuesday the launch of STAgora, a next-generation platform for infectious disease analytics.
Designed as a real-time infectious disease intelligence system, the company says that the platform combines diagnostic data with advanced statistical modelling and aims to redefine how the world detects, tracks and responds to outbreaks.
STAgora provides real-time global visualisation of infectious disease trends at the municipal, national and continental levels, based on actual diagnostic test results. It also delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customisable dashboards and real-time alert functions.
In addition to tracking individual cases, STAgora enables users to monitor outbreaks across selected regions, both local and international. This capability is designed to provide real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks.
Seegene says that it will officially debut STAgora at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place from 27 to 31 July in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
Alvotech and Advanz Pharma sign European deal for Cimzia biosimilar
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies